ClinicalTrials.gg
CompletedNCT00833664Updated May 30, 2023Results posted

Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

A Phase 1 interventional study of Terbinafine HCl 250mg tablets and Lamisil® 250 mg Tablets in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-30.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Purpose of this study os to evaluate the relative bioavailability of the test formulation of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis Pharmaceuticals), under post-prandial conditions in healthy, non-tobacco using male and female adult subjects.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, 18 years or older inclusive with a (BMI) of 30 or less.
  • Good health as determined by lack of abnormalities in health assessments performed at screening.
  • Signed and dated form, which meets all criteria of current FDA regulations
  • If female and of child bearing potential subjects must be prepared to abstain from sexual intercourse or use a reliable barrier method of (e.g. condom, IUD) during the duration of the study. Female subjects who have used oral contraceptives within 14 days or injected hormonal contraceptives within 180 days of dosing will not be allowed to participate.

Exclusion criteria

Exclusion Criteria:

  • If female, pregnant, lactating or likely to become pregnant during the study.
  • History of allergy or sensitivity to terbinafine, or history of any drug or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  • Significant history or current evidence of chronic evidence of chronic infectious disease, system disorder ot organ dysfunction.
  • Presence of gastrointestinal disease ot history of malabsorption within the last year.
  • History of psychiatric disorders occuring within the last two years that required hospitalization or medication.
  • Presence of a medical condition requiring regular treatment with prescription drugs.
  • Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes. within 30 days prior to dosing.
  • Receipt of any drug as part of a research study within 30 days prior to dosing.
  • Drug or alcohol addition requiring treatment in the past 12 months.
  • Donation or significant loss of whole blood (480 ml or more) within 30 days or plasma within 14 days prior to dosing.
  • Positive test results for drug of abuse at screening.
  • Tobacco user within 90 days of the first study dose.
  • Unable, or unwilling to tolerate multiple venipunctures.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Terbinafine

    Terbinafine 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period

    Drug: Terbinafine HCl 250mg tablets

  • Active comparator
    Lamisil®

    Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period

    Drug: Lamisil® 250 mg Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Observed Concentration - Terbinafine in Plasma

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over144 hour period

  2. AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Terbinafine in Plasma

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 144 hour period

  3. AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Terbinafine in Plasma

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 144 hour period

07

Results

Posted Aug 18, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneTerbinafine (Test) FirstLamisil® (Reference) First
Started1111
Completed1111
Not completed00
Washout: 14 Days
Participant flow — Washout: 14 Days
MilestoneTerbinafine (Test) FirstLamisil® (Reference) First
Started1111
Completed1011
Not completed10
Second Intervention
Participant flow — Second Intervention
MilestoneTerbinafine (Test) FirstLamisil® (Reference) First
Started1011
Completed1011
Not completed00

Outcome measures

PrimaryCmax - Maximum Observed Concentration - Terbinafine in Plasma

Bioequivalence based on Cmax

Time frame:
Blood samples collected over144 hour period
Reported as:
Mean · ng/mL
Cmax - Maximum Observed Concentration - Terbinafine in Plasma
ng/mLTerbinafineLamisil®
Cmax - Maximum Observed Concentration - Terbinafine in Plasma906 ± 196971 ± 417
Statistical analysis
  • Terbinafine vs Lamisil® · Test/ref ratio of ls means x 100: 98.2 · 90% CI 88.1 to 109.5Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Terbinafine in Plasma

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 144 hour period
Reported as:
Mean · ng*h/mL
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Terbinafine in Plasma
ng*h/mLTerbinafineLamisil®
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Terbinafine in Plasma4870 ± 16185953 ± 4170
Statistical analysis
  • Terbinafine vs Lamisil® · Test/ref ratio of ls means x 100: 107.6 · 90% CI 104.7 to 110.6Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Terbinafine in Plasma

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 144 hour period
Reported as:
Mean · ng*h/mL
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Terbinafine in Plasma
ng*h/mLTerbinafineLamisil®
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Terbinafine in Plasma4652 ± 19254835 ± 2795
Statistical analysis
  • Terbinafine vs Lamisil® · Test/ref ratio of ls means x 100: 98.2 · 90% CI 92.7 to 104.0Bioequivalence is established when 90% Confidence Interval falls within 80-125.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Terbinafine (Test) FirstLamisil® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years111021
>=65 years011
Sex: Female, Male
Sex: Female, Male(Participants)Terbinafine (Test) FirstLamisil® (Reference) FirstTotal
Female134
Male10818
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Terbinafine (Test) FirstLamisil® (Reference) FirstTotal
Caucasian4610
Black6511
Biracial101
Region of Enrollment
Region of Enrollment(participants)Terbinafine (Test) FirstLamisil® (Reference) FirstTotal
United States111122
08

Study locations

1 site
  • Novum Pharmaceutical Research Services
    Pittsburgh, Pennsylvania 15206-3817, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2002, a primary completion of Jan 2002 and a completion of Jan 2002. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 7 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2009
First posted
Feb 2, 2009
Start
Jan 2002
Primary completionActual
Jan 2002
CompletionActual
Jan 2002
Results first posted
Aug 18, 2009
Last update
May 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00833664
First posted
Feb 2, 2009
Start date
Jan 2002
Primary completion
Jan 2002
Completion
Jan 2002
Results posted
Aug 18, 2009
Last update
May 30, 2023

Study contacts

Shirley Ann Kennedy, M.D.
principal investigator · Novum

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion